摘要
目的：探讨齐拉西酮与利培酮治疗首发精神分裂症患者的疗效和安全性。方法将56例首发精神分裂症患者随机分为两组，研究组口服齐拉西酮治疗，对照组口服利培酮治疗，观察6周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降（ P＜0．05或0．01），治疗第4周、6周末研究组阴性症状因子分较对照组下降更显著（ P＜0．05或0．01）；治疗6周末两组显效率、有效率比较差异无显著性（P＞0．05）。两组不良反应均轻微，但研究组体质量增加发生率显著低于对照组（P＜0．01）。结论齐拉西酮与利培酮治疗首发精神分裂症疗效显著且相当，安全性高，但齐拉西酮改善阴性症状效果更显著，对体质量无明显影响，更有利于提高患者的治疗依从性。
Objective To explore the efficacy and safety of ziprasidone and risperidone in the treatment of first‐episode schizophrenia .Methods Fifty‐six first‐episode schizophrenics were randomly divided into two groups ,research group took orally ziprasidone and control group did risperidone for 6 weeks .Clinical effi‐cacies were assessed with the Positive and Negative Syndrome Scale （PANSS） before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results After treatment to‐tal and each factor scores of the PANSS of both groups lowered more significantly compared with pretreat‐ment（P〈0 .05 or 0 .01） ,so did negative symptom scores in research than control group at the end of the 4th and 6th week （P〈0 .05 or 0 .01）;there were no significant group differences in obvious effective and ef‐fective rate at the end of the 6th week （P〉0 .05） .Adverse reactions of both groups were mild ,but the in‐cidence of weight gain was significantly lower in research than control group （P〈0 .01） .Conclusion Zi‐prasidone equivalent to risperidone has an evident effect and higher safety in first‐episode schizophrenia , but it improves negative symptoms more notably ,has no influence on body mass ,is beneficial to the im‐provement of treatment compliance .
出处
《临床心身疾病杂志》
CAS
2015年第1期37-39,共3页
Journal of Clinical Psychosomatic Diseases
作者简介
赵来田，男，38岁，汉族，本科，副主任医师，院长助理，科主任。主要研究成果：发表专业论文4篇。研究方向：精神疾病诊断与治疗。
